Vestcor Inc Takes $321,000 Position in Organon & Co. (NYSE:OGN)

Vestcor Inc acquired a new position in Organon & Co. (NYSE:OGNFree Report) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 21,520 shares of the company’s stock, valued at approximately $321,000.

A number of other hedge funds have also bought and sold shares of OGN. Crossmark Global Holdings Inc. grew its stake in shares of Organon & Co. by 43.4% in the third quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company’s stock worth $385,000 after acquiring an additional 6,096 shares during the period. Victory Capital Management Inc. grew its position in Organon & Co. by 127.3% in the 3rd quarter. Victory Capital Management Inc. now owns 183,298 shares of the company’s stock worth $3,506,000 after purchasing an additional 102,663 shares during the period. KBC Group NV raised its stake in Organon & Co. by 19.5% during the 3rd quarter. KBC Group NV now owns 7,744 shares of the company’s stock valued at $148,000 after buying an additional 1,263 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of Organon & Co. by 7.9% during the 3rd quarter. Natixis Advisors LLC now owns 48,215 shares of the company’s stock valued at $922,000 after buying an additional 3,520 shares during the period. Finally, Aljian Capital Management LLC purchased a new position in shares of Organon & Co. in the 3rd quarter worth $196,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Up 2.1 %

OGN stock opened at $15.63 on Tuesday. The business’s 50-day moving average price is $15.46 and its 200-day moving average price is $16.60. The stock has a market cap of $4.03 billion, a P/E ratio of 4.69, a PEG ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10.

Organon & Co. (NYSE:OGNGet Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. On average, equities research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.17%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

Wall Street Analysts Forecast Growth

OGN has been the topic of a number of recent research reports. TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Barclays lowered their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, Morgan Stanley cut their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $20.80.

Get Our Latest Analysis on OGN

Organon & Co. Profile

(Free Report)

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Featured Stories

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.